Bath, UK – ReadyGo Diagnostics Ltd., a global leader in rapid diagnostic solutions, is pleased to announce the development of a pioneering single-tube Monkey pox (Mpox) virus detection assay. This innovative assay is a result of ReadyGo Diagnostics’ cutting-edge expertise in point-of-care testing and addresses the critical need for swift and precise diagnostics in response to the growing Mpox threat.
The new assay, designed for rapid results in under 20 minutes, seamlessly integrates with ReadyGo’s SnapCollect sample collection and processing consumable, known for its efficacy in capturing and processing viruses from saliva. It can be deployed on ReadyGo’s affordable Geo molecular platform or used as a standalone kit compatible with traditional laboratory-based molecular platforms. With the utilization of Meridian Bioscience Inc.’s Air-Dryable Direct RNA/DNA LAMP Saliva (MDX137) reagents, this assay promises exceptional accuracy and reliability, essential for effective patient isolation and treatment.
“We are thrilled to introduce this much-needed Mpox detection tool to the market,” said Dr. Ben Cobb, CEO of ReadyGo Diagnostics. “Our innovative approach harnesses the latest advancements in diagnostic technology to meet the urgent needs of healthcare providers worldwide. Our collaboration with Meridian’s innovative molecular reagents has allowed us to develop a powerful Mpox detection tool that will greatly benefit communities globally.”
The Mpox assay will undergo rigorous testing to meet international standards and is scheduled to be available in September 2024. It will be made accessible to healthcare providers and partners for distribution in cost-sensitive regions that require reliable point-of-care diagnostics. This assay is positioned to become a vital tool in early detection and outbreak management, helping to protect communities worldwide.
Media Contact:
ReadyGo Diagnostics Ltd.
Ben Cobb, CEO
Ben Reed, CCO
Email: info@readygotest.com
Website: www.readygotest.com
About ReadyGo Diagnostics Ltd.:
ReadyGo Diagnostics Ltd. is a global leader in the development of innovative rapid diagnostic tests designed to meet the demands of point-of-care settings worldwide. The company’s commitment to advancing healthcare through technology-driven solutions ensures timely and accurate diagnostics for a wide range of infectious diseases.